A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Abstract
T-cell bispecific antibodies (TCB) are engineered molecules that bind both the T-cell receptor and tumor-specific antigens. Epidermal growth factor receptor variant III (EGFRvIII) mutation is a common event in glioblastoma (GBM) and is characterized by the deletion of exons 2–7, resulting in a constitutively active receptor that promotes cell proliferation, angiogenesis, and invasion. EGFRvIII is expressed on the surface of tumor cells and is not expressed in normal tissues, making EGFRvIII an ideal neoantigen target for TCBs. We designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacologic characteristics and potent antitumor activity. EGFRvIII-TCB showed specificity for EGFRvIII and promoted tumor cell killing as well as T-cell activation and cytokine secretion only in patient-derived models expressing EGFRvIII. Moreover, EGFRvIII-TCB promoted T-cell recruitment into intracranial tumors. EGFRvIII-TCB induced tumor regression in GBM animal models, including humanized orthotopic GBM patient-derived xenograft models. Our results warrant the clinical testing of EGFRvIII-TCB for the treatment of EGFRvIII-expressing GBMs.
- Research Organization:
- H & T ENTERPRISES, INC.
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- SC0000001
- OSTI ID:
- 2425403
- Journal Information:
- Molecular Cancer Therapeutics, Journal Name: Molecular Cancer Therapeutics Journal Issue: 10 Vol. 21; ISSN 1535-7163
- Publisher:
- American Association for Cancer Research (AACR)
- Country of Publication:
- United States
- Language:
- English
Similar Records
GENE-43. Targeting GABPb1L Inhibits In Vivo Growth of TERT Promoter Mutant Glioblastoma
Generation of regulable EGFRvIII targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma